BRANFORD, Conn., Aug. 14, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the second quarter ended June 30, 2023.
Francisco Salva, Chief Executive Officer of Azitra, commented, "We are extremely pleased with the exciting recent progress at Azitra, and we are thrilled to have closed on our initial public offering in June. This year, we have demonstrated the potential of our regulatory, manufacturing, and clinical capabilities that resulted in a new IND for ATR-12 for a Phase 1b clinical trial in Netherton syndrome. Additionally, we are very pleased with the recent progress of our platform and collaboration with Bayer."
Recent Business Highlights
Financial Results for the Three Months Ended June 30, 2023
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the presentation of data from the Phase 1b study of ATR-12, the filing of an IND application, and the presentation of data from our Phase 1b for ATR-04, the IND filing for ATR-01, the timing of having a signed license agreement with Bayer, and statements about our clinical and pre-clinical programs, and corporate and clinical/pre-clinical strategies.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1b trial for ATR-12 and pre-clinical studies of other product candidates and obtain required approval before commercialization; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described in its registration statement on Form S-1, which is on file with the SEC, and in its most recent quarterly report on Form 10-Q to be filed with the SEC. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Company Contact
Norman Staskey
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Condensed Consolidated Statement of Operations | |||||||
(Unaudited) | |||||||
Three months Ended June 30, | |||||||
2023 | 2022 | ||||||
Service revenue – related party | $ | 172,000 | $ | 85,000 | |||
Total revenue | 172,000 | 85,000 | |||||
Operating expenses: | |||||||
General and administrative | 844,640 | 667,940 | |||||
Research and development | 812,836 | 1,505,447 | |||||
Total operating expenses | 1,657,476 | 2,173,387 | |||||
Loss from operations | (1,485,476) | (2,088,387) | |||||
Other income (expense): | |||||||
Interest income | 265 | 335 | |||||
Interest expense | (76,187) | (17,811) | |||||
Employee retention credit | - | 229,813 | |||||
Other income | 1,600 | - | |||||
Forgiveness of accounts payable | 56,285 | - | |||||
Change in fair value of convertible note | (2,830,100) | - | |||||
Other expense | (95,915) | (14,103) | |||||
Total other income (expense) | (2,944,052) | 198,234 | |||||
Net loss before income taxes | (4,429,528) | (1,890,153) | |||||
Income tax benefit (expense) | - | ||||||
Net loss | $ | (4,429,528) | (1,890,153) | ||||
Dividends on preferred stock | (643,267) | (692,246) | |||||
Net loss attributable to common shareholders | $ | (5,072,795) | (2,582,399) | ||||
Net loss per Share, basic and diluted | (2.36) | (2.45) | |||||
Weighted average common stock outstanding, basic and diluted | $ | 2,147,526 | $ | 1,055,454 |
Condensed Consolidated Balance Sheets | |||||||
(Unaudited) | |||||||
June 30, | December 31, | ||||||
2023 | 2022 | ||||||
Assets | |||||||
Current Assets: | |||||||
Cash and cash equivalents | $ | 6,290,355 | $ | 3,492,656 | |||
Other receivables | 501,288 | 266,208 | |||||
Prepaid expenses and other current assets | 48,523 | 377,019 | |||||
Total current assets | $ | 6,840,166 | $ | 4,135,883 | |||
Property and equipment, net | 803,107 | 846,958 | |||||
Other assets | 2,186,284 | 2,184,602 | |||||
Total assets | $ | 9,829,557 | $ | 7,167,443 | |||
Liabilities, preferred stock, and stockholders' equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 364,183 | $ | 784,687 | |||
Current operating lease liability | 298,047 | 287,384 | |||||
Accrued expenses | 767,721 | 993,961 | |||||
Contract liabilities | 310,700 | 156,000 | |||||
Total current liabilities | 1,740,651 | 2,222,032 | |||||
Long-term operating lease liability | 693,609 | 840,896 | |||||
Warrant liability | 158,994 | 70,283 | |||||
Convertible notes payable, net | 0 | 6,600,000 | |||||
Total liabilities | 2,593,254 | 9,733,211 | |||||
Stockholders' equity (deficit) | |||||||
Preferred stock | 0 | 33,694,542 | |||||
Common stock | 1,210 | 104 | |||||
Additional paid-in capital | 51,436,352 | 1,054,138 | |||||
Accumulated deficit | (44,201,259) | (37,314,552) | |||||
Total stockholders' equity (deficit) | 7,236,303 | (36,260,310) | |||||
Total liabilities, preferred stock and stockholders' equity (deficit) | $ | 9,829,557 | $ | 7,167,443 | |||
Last Trade: | US$0.47 |
Daily Change: | 0.0046 0.99 |
Daily Volume: | 52,205 |
Market Cap: | US$3.590M |
November 12, 2024 October 29, 2024 September 24, 2024 September 18, 2024 September 06, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB